Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 242 citing Raskin: A randomized trial of rosiglitazone therapy in patients with inadequately controlled.... (0.08 sec) 

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular …

- hopkinsmedicine.org [PDF] 
SE Nissen, K Wolski - New England Journal of Medicine, 2007 - content.nejm.org
From the Cleveland Clinic, Cleveland. Ad- dress reprint requests to Dr. Nissen
at the Department of Cardiovascular Medi- cine, Cleveland Clinic, 9500 Euclid
Ave., Cleveland, OH 44195, or at nissens@ccf. org.
Cited by 1322 - Related articles - BL Direct - All 83 versions

Thiazolidinediones


H Yki-Jarvinen - New England Journal of Medicine, 2004 - content.nejm.org
Insulin resistance both precedes and predicts type 2 diabetes mellitus. 1
Although exercise and weight loss ameliorate insulin resistance and may in some
cases prevent or delay onset of the disease, 2 therapy that combats insulin ...
Cited by 838 - Related articles - BL Direct - All 6 versions

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus …


RW Nesto, D Bell, RO Bonow, V Fonseca, SM … - Circulation, 2003 - Am Heart Assoc
These beneficial effects of TZDs on glycemia and cardiovascular risk factors
have made them attractive agents in patients with type 2 diabetes who are at
high risk for CVD. There is a growing recognition, however, that edema can ...
Cited by 569 - Related articles - BL Direct - All 17 versions

Metabolic and additional vascular effects of thiazolidinediones

- adisonline.com [PDF] 
F Martens, FLJ Visseren, J Lemay, EJP De … - Drugs, 2002 - ingentaconnect.com
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . 1464 1. Peroxisome Proliferator-Activated
Receptors (PPARs) . . . . . . . . . . . . . . . . . . . . . . . . . . 1465 ...
Cited by 251 - Related articles - BL Direct - All 9 versions

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors


E Chiquette, G Ramirez, R DeFronzo - Archives of internal medicine, 2004 - archinte.highwire.org
You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ...
Cited by 197 - Related articles - BL Direct - All 6 versions

[PDF] Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double- …


J Sutinen, AM Hakkinen, J Westerbacka, A … - Antiviral Therapy, 2003 - mapleleafmedical.com
Highly active antiretroviral therapy (HAART) is associated with metabolic
adverse events such as insulin resistance and lipodystrophy, that is, atrophy of
subcutaneous fat and accumulation of intra-abdominal fat. Currently, there ...
Cited by 187 - Related articles - View as HTML - BL Direct - All 8 versions

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

- adisonline.com [PDF] 
M Diamant, RJ Heine - Drugs, 2003 - ingentaconnect.com
Abstract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . 1373 1. Thiazolidinediones: Basic Aspects and Mode of Action ...
Cited by 174 - Related articles - BL Direct - All 9 versions

Glitazones: clinical effects and molecular mechanisms


M Stumvoll, HU Häring - Annals of Medicine, 2002 - informahealthcare.com
With the thiazolidinediones rosiglitazone and pioglitazone a novel treatment
modality for type 2 diabetes has become available in many countries. As
monotherapy, fasting blood glucose and glycosylated hemoglobin (HbA1c), on ...
Cited by 140 - Related articles - BL Direct - All 7 versions

Thiazolidinediones and blood lipids in type 2 diabetes

- ahajournals.org
JPH van Wijk, EJP de Koning, EP Martens, TJ … - Arteriosclerosis, thrombosis, and vascular biology, 2003 - Am Heart Assoc
We evaluated study population characteristics and treatment effects on blood
lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO)
was investigated in patients with type 2 diabetes. We performed a summary ...
Cited by 131 - Related articles - BL Direct - All 7 versions

Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush …


PHM van de Weijer, R Barentsen - Maturitas, 2002 - Elsevier
Objectives: To investigate the effectiveness and safety of a red clover
isoflavone dietary supplement (Promensil, Novogen Ltd., Australia) versus
placebo on the change in hot flush frequency in postmenopausal women. ...
Cited by 132 - Related articles - All 16 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google